Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DTILNYSE:IBIONASDAQ:ICCCNASDAQ:XCUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDTILPrecision BioSciences$4.79+1.9%$5.07$3.61▼$11.09$53.11M1.48188,055 shs240,913 shsIBIOiBio$0.77-14.3%$0.88$0.64▼$6.89$12.74M0.96448,033 shs926,644 shsICCCImmuCell$7.60+24.2%$5.86$3.34▼$7.60$68.68M0.323,047 shs204,766 shsXCURExicure$7.47-2.0%$10.16$1.44▼$36.00$47.19M3.71560,560 shs5,486 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDTILPrecision BioSciences+1.91%-2.24%+3.01%-12.11%-52.57%IBIOiBio-14.33%-16.93%+0.08%-83.35%-66.18%ICCCImmuCell+21.68%+17.28%+23.78%+54.79%+78.82%XCURExicure-1.97%-14.73%-27.79%-46.83%+2,163.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDTILPrecision BioSciences4.1362 of 5 stars3.53.00.04.60.61.71.3IBIOiBio1.5731 of 5 stars3.50.00.00.01.80.00.6ICCCImmuCell0.6242 of 5 stars0.05.00.00.02.20.00.0XCURExicure1.5665 of 5 stars0.04.00.04.72.60.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDTILPrecision BioSciences 3.00Buy$47.00881.21% UpsideIBIOiBio 3.00Buy$4.30457.72% UpsideICCCImmuCell 0.00N/AN/AN/AXCURExicure 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest IBIO, DTIL, ICCC, and XCUR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.005/5/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/28/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDTILPrecision BioSciences$68.70M0.77N/AN/A$6.87 per share0.70IBIOiBio$375K33.96N/AN/A$1.41 per share0.55ICCCImmuCell$26.49M2.59$0.06 per share118.20$3.09 per share2.46XCURExicure$500K94.42N/AN/A$1.12 per share6.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDTILPrecision BioSciences$7.17M-$2.01N/AN/AN/A-42.99%-69.26%-29.30%7/30/2025 (Estimated)IBIOiBio-$24.91MN/A0.00N/AN/AN/A-73.15%-45.51%N/AICCCImmuCell-$2.16M-$0.07N/A∞N/A-1.00%-1.02%-0.61%8/12/2025 (Estimated)XCURExicure-$9.70M-$4.81N/A∞N/AN/A-319.72%-82.41%8/11/2025 (Estimated)Latest IBIO, DTIL, ICCC, and XCUR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025DTILPrecision BioSciences-$0.43-$2.21-$1.78-$2.21$5.00 million$0.03 million5/14/2025Q1 2025ICCCImmuCellN/A$0.16N/A$0.16N/A$8.07 million3/26/2025Q4 2024DTILPrecision BioSciences-$2.09-$3.20-$1.11-$2.22$4.28 million$3.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDTILPrecision BioSciencesN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/AICCCImmuCellN/AN/AN/AN/AN/AXCURExicureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDTILPrecision BioSciences0.456.626.62IBIOiBio0.051.761.76ICCCImmuCell0.304.122.21XCURExicureN/A4.454.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDTILPrecision BioSciences37.99%IBIOiBio7.90%ICCCImmuCell13.47%XCURExicure42.82%Insider OwnershipCompanyInsider OwnershipDTILPrecision BioSciences4.50%IBIOiBio0.58%ICCCImmuCell6.60%XCURExicure3.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDTILPrecision BioSciences20011.09 million10.59 millionNo DataIBIOiBio10016.52 million9.82 millionN/AICCCImmuCell709.04 million8.44 millionNot OptionableXCURExicure506.32 million6.07 millionNot OptionableIBIO, DTIL, ICCC, and XCUR HeadlinesRecent News About These CompaniesExicure (NASDAQ:XCUR) Stock Price Down 5.8% - Here's WhyJune 18 at 1:51 AM | marketbeat.comExicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-QMay 28, 2025 | businesswire.comExicure (NASDAQ:XCUR) Trading Down 4.5% - Here's WhyMay 28, 2025 | marketbeat.comWhy Exicure Inc. (XCUR) Soared on MondayApril 22, 2025 | msn.comExicure’s subsidiary, GPCR Therapeutics doses 19th patient in its phase 2 study of GPC-100 in multiple myelomaApril 16, 2025 | pharmabiz.comExicure to initiate new clinical trial in acute myeloid leukaemia with GPC-100April 15, 2025 | pharmabiz.comExicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple MyelomaApril 14, 2025 | businesswire.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in ...April 11, 2025 | gurufocus.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)April 11, 2025 | investing.comExicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)April 11, 2025 | businesswire.comWednesday’s Insider Moves: Top Buys and Sells in US StocksMarch 27, 2025 | investing.comExicure, Inc. Reports Full Year 2024 Financial ResultsMarch 18, 2025 | gurufocus.comExicure secures Australian patent for cancer treatmentMarch 15, 2025 | investing.comExicure announces issuance of new patent in AustraliaMarch 15, 2025 | markets.businessinsider.comExicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in AustraliaMarch 13, 2025 | gurufocus.comKuehn Law Encourages Investors of Exicure, Inc. to Contact Law FirmJanuary 27, 2025 | markets.businessinsider.comExicure announces purchase agreement with GPCR TherapeuticsJanuary 24, 2025 | markets.businessinsider.comCORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.January 23, 2025 | businesswire.comExicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.January 22, 2025 | businesswire.comWhen the Price of (XCUR) Talks, People ListenJanuary 21, 2025 | news.stocktradersdaily.comWhen (XCUR) Moves Investors should ListenJanuary 11, 2025 | news.stocktradersdaily.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIBIO, DTIL, ICCC, and XCUR Company DescriptionsPrecision BioSciences NASDAQ:DTIL$4.79 +0.09 (+1.91%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$4.75 -0.04 (-0.84%) As of 06/20/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.iBio NYSE:IBIO$0.77 -0.13 (-14.33%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.78 +0.01 (+1.82%) As of 06/20/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.ImmuCell NASDAQ:ICCC$7.60 +1.48 (+24.18%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$7.47 -0.13 (-1.71%) As of 06/20/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.Exicure NASDAQ:XCUR$7.47 -0.15 (-1.97%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$8.27 +0.80 (+10.72%) As of 06/20/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
